MX2015002755A - 1,3-dioxanomorfidas y 1,3-dioxanocodidas. - Google Patents

1,3-dioxanomorfidas y 1,3-dioxanocodidas.

Info

Publication number
MX2015002755A
MX2015002755A MX2015002755A MX2015002755A MX2015002755A MX 2015002755 A MX2015002755 A MX 2015002755A MX 2015002755 A MX2015002755 A MX 2015002755A MX 2015002755 A MX2015002755 A MX 2015002755A MX 2015002755 A MX2015002755 A MX 2015002755A
Authority
MX
Mexico
Prior art keywords
compounds
directed
formula
dioxanomorphides
dioxanocodides
Prior art date
Application number
MX2015002755A
Other languages
English (en)
Inventor
Helge A Reisch
Original Assignee
Rhodes Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Tech filed Critical Rhodes Tech
Publication of MX2015002755A publication Critical patent/MX2015002755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La solicitud está dirigida a compuestos de Fórmula I (ver Fórmula) y sales, prodrogas y solvatos farmacéuticamente aceptables de los mismos, donde G, R2-R5, y / son definidos como se describe en la memoria descriptiva. La invención también está dirigida al uso de compuestos de Fórmula I como intermediarios sintéticos o para tratar trastornos en la respuesta a la modulación de uno o más receptores opioides. Ciertos compuestos de la presente invención son especialmente útiles para el tratamiento del dolor.
MX2015002755A 2012-08-27 2013-08-27 1,3-dioxanomorfidas y 1,3-dioxanocodidas. MX2015002755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261693593P 2012-08-27 2012-08-27
PCT/IB2013/001877 WO2014033530A1 (en) 2012-08-27 2013-08-27 1,3-dioxanomorphides and 1,3-dioxanocodides

Publications (1)

Publication Number Publication Date
MX2015002755A true MX2015002755A (es) 2017-05-12

Family

ID=49385295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002755A MX2015002755A (es) 2012-08-27 2013-08-27 1,3-dioxanomorfidas y 1,3-dioxanocodidas.

Country Status (9)

Country Link
US (1) US9315514B2 (es)
EP (1) EP2888267B1 (es)
JP (1) JP5982063B2 (es)
AU (1) AU2013308174B2 (es)
CA (1) CA2881034A1 (es)
ES (1) ES2619636T3 (es)
IL (1) IL237068A (es)
MX (1) MX2015002755A (es)
WO (1) WO2014033530A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038813A1 (en) 2010-09-21 2012-03-29 Purdue Pharma L.P. Buprenorphine analogs
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
JP6317755B2 (ja) 2012-12-07 2018-04-25 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
CA2934913A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
US9988392B2 (en) 2013-12-26 2018-06-05 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
JP2021521170A (ja) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
MX2021009371A (es) 2019-02-12 2021-09-10 Sumitomo Pharma Oncology Inc Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
NL289751A (es) 1962-03-02
DE1938219A1 (de) 1968-07-26 1970-02-12 Sankyo Co Verfahren zur Herstellung von 14-Hydroxy-normorphinonderivaten
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3562279A (en) 1969-05-15 1971-02-09 American Cyanamid Co Substituted 7,8-dihydro - 6 - methoxy-6,14-endo(etheno or ethano)morphide - 7-ketones and n-cycloalkylmethyl - 7,8-dihydro - 6 - methoxy-6,14-endo(etheno or ethano) norcodide-7-ketones
US3560506A (en) 1969-05-15 1971-02-02 American Cyanamid Co Substituted 7-(di(lower alkoxy)methyl)-and 7-(lower alkylenedioxymethyl)-7,8-dihydro-6-methoxy-6,14-endo-(etheno or ethano) codides and morphides
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2229770A1 (de) 1972-06-19 1974-01-10 Boehringer Sohn Ingelheim N-(heteroarylmethyl)-7alpha-acyl6,14-endoaethenotetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4440931A (en) * 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-3-methoxy or 3-hydroxy-4,5α-epoxy-6β-hydroxy-7α-hydroxymethyl-17-methyl or 17-cycloalkylmethylmorphinans
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CS277222B6 (cs) 1990-05-24 1992-12-16 Vyzk Ustav Farm Biochem Sp Způsob výroby buprenorfinu
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CZ58793A3 (en) 1993-04-05 1995-07-12 Galena Process for preparing (6r, 7r, 14s)-17-cyclopropylmethyl 7,8-dihydro-7-/(1s)-1-hydroxy-1,2,2-trimethylpropyl/ -6-0-methyl-6,14-ethano-17-normorphine
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ATE444296T1 (de) * 2002-10-25 2009-10-15 Euro Celtique Sa Analoga und prodrugs von buprenorphin
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
US20080312411A1 (en) 2005-02-16 2008-12-18 Andreas Wolf Use of Activated Polymers for Separation of Protein and Polypeptide Multimers
CZ300995B6 (cs) 2005-12-20 2009-10-07 Zentiva, A. S. Zpusob výroby (2S,7´R)-2-[17´-(cyklopropylmethyl)-3´-hydroxy-4´,5´-epoxy-6´-methoxy-6´,14´-endoethanomorfinan-7´-yl]-3,3-dimethylbutan-2-olu
ES2329296T3 (es) 2006-01-05 2009-11-24 Mallinckrodt, Inc. El uso de oripavina como material de partida para buprenorfina.
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
JP2010510326A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド ４，５−エポキシ−モルフィナニウム類似体のｎ−オキシド類
PL2342207T3 (pl) 2008-09-30 2016-05-31 SpecGx LLC Sposoby alkilowania norbuprenorfiny ze zmniejszonym powstawaniem zanieczyszczeń
WO2012038813A1 (en) * 2010-09-21 2012-03-29 Purdue Pharma L.P. Buprenorphine analogs
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides

Also Published As

Publication number Publication date
IL237068A (en) 2017-12-31
EP2888267B1 (en) 2017-01-18
JP2015526500A (ja) 2015-09-10
JP5982063B2 (ja) 2016-08-31
AU2013308174A1 (en) 2015-04-09
ES2619636T3 (es) 2017-06-26
EP2888267A1 (en) 2015-07-01
US20140057932A1 (en) 2014-02-27
US9315514B2 (en) 2016-04-19
CA2881034A1 (en) 2014-03-06
WO2014033530A1 (en) 2014-03-06
AU2013308174B2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MX2015002755A (es) 1,3-dioxanomorfidas y 1,3-dioxanocodidas.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
WO2014091298A3 (en) Nitrogen containing morphinan derivatives and the use thereof
WO2015100092A3 (en) 7-beta analogs of orvinols
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
PH12015502036A1 (en) Inhibitors of the kynurenine pathway
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
MX2017005668A (es) Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2.
WO2012035421A3 (en) Pyridine compounds and the uses thereof
MX359882B (es) Amidas como moduladores de canales de sodio.
NZ701122A (en) Agents for treating disorders involving modulation of ryanodine receptors
GEP201706638B (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
MX2011008602A (es) Metodos de tratamiento de condiciones relacionadas con el cabello.
MX2013003923A (es) Compuestos de quinazolina como bloqueadores del canal de sodio.
WO2011158108A3 (en) Aryl substituted indoles and their use as blockers of sodium channels
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
IN2015DN03145A (es)
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MY181847A (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
AR083430A1 (es) Compuestos utiles como agentes terapeuticos para enfermedades, trastornos y condiciones que pueden tratarse inter alia por modulacion de receptores opiaceos, acetilcolinesterasa, receptores de nmda, y recaptacion de serotonina y/o norepinefrina; y composiciones farmaceuticas que comprenden tales compuestos
TN2011000521A1 (en) Fused pyrimidine derivatives as trpv3 modulators